Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab

In conclusion, during re-treatment with erenumab 140 mg, migraine pain intensity and disability documented a significant and progressive improvement. Our data confirm the long-term efficacy, although in a very limited case series, of monoclonal antibodies targeting CGRP beyond headache frequency reduction.Eur Neurol
Source: European Neurology - Category: Neurology Source Type: research